Sudarshan Chemical Industries Ltd Q4 FY26 Earnings Analysis

Published 7 Aug 2026 | Chemicals & Petrochemicals | Market Cap: ₹8.6K Cr

Price

1,130

Market Cap

₹8.6K Cr

P/E Ratio

465.3

Earnings Summary

- Legacy Sudarshan business: Expected to return to its long-term growth rate of around 10-11% CAGR, with growth resuming from Q4 FY '26 onwards. - Legacy Sudarshan business is expected to return to a long-term sustainable growth rate of around 10%-11% CAGR (Rajesh Rathi, Page 13). - The company anticipates gradual improvement in operating performance with cost optimization and working capital initiatives, resulting in building up to ~10% margin or close to EUR 90-100 million EBITDA over the next few years (Page 14). - Synergies and cost savings pipeline is strong, with a 3-4 year target to deliver EUR 90-100 million EBITDA largely through cost reduction and normalized sales (Page 9). - The impact of inventory reduction (EUR 30-40 million reduction) will positively affect cash flow and net debt but may temporarily suppress reported EBITDA by EUR 9-12 million over the next 3 quarters, normalizing thereafter (Page 6-7). - Confident of improved profitability from Q4 FY26 onwards supported by customer restocking and demand recovery (Page 14).

📊 Revenue & Sales Performance

- Legacy Sudarshan business: Expected to return to its long-term growth rate of around 10-11% CAGR, with growth resuming from Q4 FY '26 onwards. - Acquired business (Heubach): Anticipated sales growth after inventory destocking phase; production volumes will initially lag sales, normalizing post-Q2 FY '27. - Demand Improvement: Customers showed subdued demand in first 7-8 months but demand improved substantially after November, indicating recovery. - New product investments in legacy business are performing well, with growing demand and potential margin improvements. - Overall revenue growth is expected to be gradual and back-ended with a ramp-up as cost optimization and synergies take effect. - Industry-wide demand challenges are seen as temporary; normal buying patterns expected to resume, supporting volume growth.

📈 Profitability & Margins

- Legacy Sudarshan business is expected to return to a long-term sustainable growth rate of around 10%-11% CAGR (Rajesh Rathi, Page 13). - The company anticipates gradual improvement in operating performance with cost optimization and working capital initiatives, resulting in building up to ~10% margin or close to EUR 90-100 million EBITDA over the next few years (Page 14). - Synergies and cost savings pipeline is strong, with a 3-4 year target to deliver EUR 90-100 million EBITDA largely through cost reduction and normalized sales (Page 9). - The impact of inventory reduction (EUR 30-40 million reduction) will positively affect cash flow and net debt but may temporarily suppress reported EBITDA by EUR 9-12 million over the next 3 quarters, normalizing thereafter (Page 6-7). - Confident of improved profitability from Q4 FY26 onwards supported by customer restocking and demand recovery (Page 14). - EPS was negative INR 1.4 in the reported period but outlook is positive with margin expansion and demand normalization (Page 6).

🏗️ Capital Expenditure Plans

- Sudarshan Chemical Industries is focusing on cost reduction and value capture initiatives across operations, procurement, organization, IT, and fixed costs, aiming for EUR 90-100 million EBITDA in 3-4 years. - The company has inaugurated a Global Capability Center (GCC) on February 4, 2026, aiming to ramp up operations over the next year and improve productivity and response time via digital innovation. - There is a major initiative to harmonize multiple SAP systems into one by December 2026, enhancing efficiency by simplifying invoicing and process integration. - Manufacturing footprint rationalization has been largely completed, such as rightsizing Frankfurt operations and transferring production to India; no further major manufacturing changes planned. - Inventory liquidation is underway to reduce working capital and net debt, with expected positive balance sheet impact but short-term P&L impact due to overhead absorption. - No explicit mention of new capital expenditure on production capacity expansion, focusing more on operational optimization and integration.

💰 Fundraising & Capital Structure

- The transcript does not explicitly mention any current or planned new fundraising through debt or equity. - Rajesh Rathi and other management highlighted focus on reducing net debt by liquidating inventory of EUR 30-40 million, which should improve balance sheet and reduce working capital. - Interest cost on borrowings is currently around 5.75% to 6% (excluding IndAS lease accounting costs). - No specific mention of any equity issuance or debt refinancing plans. - Management is focused on cost optimization, working capital improvements, and operational efficiencies to improve financial metrics rather than relying on new capital raising at this point.

📋 Order Book & Pipeline

- Management expressed confidence in demand improvement starting January and early February, indicating a positive trend in order inflow. - Customers had promised to start buying after January, reflecting an uptick in orderbook. - The subdued demand in prior quarters was mainly due to customer destocking rather than weak end-market orders. - There is no explicit mention of a large existing order backlog or pending orders; confidence seems based on renewed customer buying behavior and market recovery. - The company expects demand normalization, supported by customer trust and improved supply chain processes. - Overall, orderbook visibility appears positive for Q4 FY26 and beyond, driven by genuine demand recovery rather than one-time restocking.

Key Metrics

Frequently Asked Questions

What were Sudarshan Chemical Industries Ltd Q4 FY26 results?

- Legacy Sudarshan business: Expected to return to its long-term growth rate of around 10-11% CAGR, with growth resuming from Q4 FY '26 onwards. - Legacy Sudarshan business is expected to return to a long-term sustainable growth rate of around 10%-11% CAGR (Rajesh Rathi, Page 13). - The company anticipates gradual improvement in operating performance with cost optimization and working capital initiatives, resulting in building up to ~10% margin or close to EUR 90-100 million EBITDA over the next few years (Page 14). - Synergies and cost savings pipeline is strong, with a 3-4 year target to deliver EUR 90-100 million EBITDA largely through cost reduction and normalized sales (Page 9). - The impact of inventory reduction (EUR 30-40 million reduction) will positively affect cash flow and net debt but may temporarily suppress reported EBITDA by EUR 9-12 million over the next 3 quarters, normalizing thereafter (Page 6-7). - Confident of improved profitability from Q4 FY26 onwards supported by customer restocking and demand recovery (Page 14).

What is Sudarshan Chemical Industries Ltd share price analysis?

Sudarshan Chemical Industries Ltd currently shows a neutral. The stock trades at a P/E of 465.3 with a market cap of ₹8,633. Investors should review the full earnings analysis for detailed insights.

Is Sudarshan Chemical Industries Ltd planning capital expenditure?

- Sudarshan Chemical Industries is focusing on cost reduction and value capture initiatives across operations, procurement, organization, IT, and fixed costs, aiming for EUR 90-100 million EBITDA in 3-4 years.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.

What Sudarshan Chemical Industries Ltd's management said in earlier quarters

Others in Chemicals & Petrochemicals this season

  • Supreme Petrochem Ltd (Q4 FY26)

    Supreme Petrochem Ltd Q4 FY26 quarterly results analysis. - Volume growth target for FY'27-28 is around 10%, assuming ABS plant commissioning by end of current

  • Silkflex Polymer (Q4 FY26)

    Silkflex Polymer Q4 FY26 quarterly results analysis. - Both textile ink and wood coating segments are expected to grow strongly: 15-20% growth in textile inks a

  • Archean Chemical Industries Ltd (Q4 FY26)

    Archean Chemical Q4 FY26 quarterly results analysis. - The company aims to increase elemental bromine production to north of 18,000 tons next year, with a mediu

  • Epigral Ltd (Q4 FY26)

    Epigral Q4 FY26 quarterly results analysis. - FY '27 expected to see good volume growth as FY '26 volumes were muted due to early/prolonged monsoon and subdued